WH

WILLIAM HIBBS

ALKERMES, INC. · Waltham, MA · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
3
9 agencies contacted
Activity
filings by quarter
Works on

Background

Career
Waltham, MA
2024 - present

Specific issues

Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA Implementation and efficiency improvements at the FDA;
Health Issues · 2024 Q3
Expand funding and flexibility to address all substance use disorders;
Alcohol and Drug Abuse · 2024 Q3
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R.8580 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; PDUFA Implementation and efficiency improvements at the FDA;
Health Issues · 2024 Q2
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2025; Support FDA efficiency reforms
Health Issues · 2024 Q1

Clients

2024 · 3 filings
$██,███ / qtrUnlock

Filing history

2024 Q3
ALKERMES, INC.
Q3lda.gov →
2024 Q2
ALKERMES, INC.
Q2lda.gov →
2024 Q1
ALKERMES, INC.
Q1lda.gov →
Showing recent filings · full history on lda.gov